LifeSci Biotechnology Clinical Trials Index
The LifeSci Biotechnology Clinical Trials Index ("LSCIBC") is an equal weighted index that is designed to measure the equity market performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering that is in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development. The inception date for LSCIBC was November 3, 2014.
|Dynavax Technologies Corp||DVAX||2.76%|
|Arena Pharmaceuticals Inc||ARNA||2.52%|
|Sangamo Therapeutics Inc||SGMO||2.45%|
|Sage Therapeutics Inc||SAGE||2.34%|
|Blueprint Medicines Corp||BPMC||2.18%|
|Juno Therapeutics Inc||JUNO||2.17%|